Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1Phase 1/2 1

Status

Completed 4Withdrawn 1Unknown 1

Sponsor Class

NIH 16OTHER 6INDUSTRY 4NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 1Other solid neoplasm 1Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Neoplasms 2Solid Tumors 1Skin Neoplasms 1Melanoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Bronchiolitis Obliterans Syndrome 1

Interventions

Paclitaxel 490Carboplatin 436Gemcitabine 394Docetaxel 385Cisplatin 360pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × INDUSTRY × oblimersen × Clear all
NCT00636545 2012-04-06

Genasense as a 2-hour Intravenous Infusion in Subjects With Solid Tumors

Genta Incorporated

Phase 1 Completed
25 enrolled
Other solid neoplasm

Solid Tumors

NCT00518895 2011-11-07

AGENDA

Genta Incorporated

Phase 3 Completed
300 enrolled
Dermatologic

Melanoma, Skin Neoplasms

NCT00021749 2009-11-13

Phase I/II Study of Genasense in Patients With Chronic Lymphocytic Leukemia

Genta Incorporated

Phase 1/2 Completed
40 enrolled
LymphoidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00543231 2007-10-12

A Phase I Study of G3139 Subcutaneous in Solid Tumors

Genta Incorporated

Phase 1 Completed
8 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡